MarketCap
Facebook
X
Telegram
Krystal Biotech Financial Ratios 2025-2011 | KRYS
Brief overview of Krystal Biotech's market valuation
The comparison uses the five latest available annual observations between 2021 and 2025.
The latest available valuation ratios are P/E 41.31x (median 56.33x), P/S 21.75x (median 21.75x), P/B 6.94x (median 5.31x). Ratios sit near their own comparison base, with an average deviation of 0% from five-year medians.
The 1/P/E calculation produces a 2.4% earnings yield. It does not capture future growth or capital structure.
Current measures of operating quality are ROE 16.8%, ROA 15.4%, ROCE 13.2%. Capital returns look adequate and support overall financial resilience.
Price, earnings and growth produce a PEG of 2.05x. A high value reduces the cushion if growth slows.
A shorter cycle, from 151.3 days to 108.9 days, indicates faster release of cash from operations.
Overall assessment
Krystal Biotech's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.
Annual Financial Ratios Krystal Biotech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
41.3 | 56.3 | 392.8 | -14.3 | -20.3 | -46.1 | -44.0 | -23.5 | -6.8 | - | - | - | - | - | - |
P/S |
21.7 | 17.3 | 84.7 | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
7.1 | 3.1 | 0.4 | -5.5 | -3.1 | -1.7 | -1.2 | -1.0 | -1.5 | -1.3 | - | - | - | - | - |
EV (Enterprise Value) |
8.08 B | 4.79 B | 3.98 B | 1.87 B | 1.1 B | 1.23 B | 658 M | 155 M | 4.87 M | -30 K | - | - | - | - | - |
EBITDA per Share |
5.77 | 2.51 | -3.85 | -5.54 | -2.99 | -1.66 | -1.34 | -1.05 | -0.886 | - | - | - | - | - | - |
EV/EBITDA |
48.4 | 66.8 | -38.0 | -13.3 | -16.6 | -35.4 | -30.6 | -12.9 | -0.9 | - | - | - | - | - | - |
PEG |
2.07 | -42.91 | 10.54 | -0.3 | - | -0.62 | -1.86 | 0.68 | -0.01 | - | - | - | - | - | - |
P/B |
6.9 | 5.3 | 5.5 | 3.8 | 2.4 | 5.1 | 4.1 | 2.3 | 1.1 | - | - | - | - | - | - |
P/CF |
42.1 | 40.7 | -48.4 | -19.9 | -29.4 | -56.8 | -33.4 | -21.9 | -13.1 | - | - | - | - | - | - |
ROE % |
16.80 | 9.42 | 1.40 | -26.80 | -11.72 | -11.01 | -9.41 | -9.62 | -16.01 | - | - | - | - | - | - |
ROA % |
15.36 | 8.44 | 1.34 | -25.06 | -11.11 | -10.35 | -9.13 | -9.38 | -15.80 | - | - | - | - | - | - |
ROCE % |
13.23 | 6.95 | -14.08 | -27.80 | -11.50 | -11.30 | -10.73 | -10.50 | -9.65 | - | - | - | - | - | - |
Current Ratio |
11.7 | 9.6 | 20.6 | 15.4 | 19.1 | 16.6 | 58.9 | 43.4 | 78.0 | - | - | - | - | - | - |
DSO |
108.9 | 92.2 | 151.3 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
108.9 | 92.2 | 151.3 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
108.9 | 92.2 | 151.3 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Krystal Biotech
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.85 | 1.91 | 2.74 | 1.33 | 1.24 | - | 0.95 | 0.54 | 0.03 | - | 2.88 | -1.25 | -1.76 | - | -1.17 | -1.1 | -1.99 | - | -0.7 | -0.74 | -0.74 | - | -0.49 | -0.37 | -0.31 | - | -0.25 | -0.37 | -0.29 | - | -0.26 | -0.22 | -0.21 | - | -1.26 | -0.22 | -0.14 | - | -8.48 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
2.03 | 1.89 | 1.48 | 1.4 | 1.3 | - | 0.83 | 0.36 | -0.19 | - | -0.88 | -1.38 | -1.86 | - | -1.2 | -1.11 | -1.96 | - | -0.62 | -0.68 | -0.65 | - | -0.42 | -0.33 | -0.32 | - | -0.27 | -0.37 | -0.32 | - | -0.28 | -0.24 | -0.22 | - | -0.5 | -0.2 | -0.13 | - | -8.48 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
19.07 | 18.67 | 17.36 | 12.24 | 8.67 | 5.04 | 15.72 | 7.57 | -3.54 | -3.66 | -9.18 | -24.88 | -28.91 | -19.66 | -23.47 | -21.86 | -20.51 | -11.40 | -14.69 | -13.21 | -11.13 | -7.46 | -9.56 | -8.91 | -8.60 | -6.77 | -9.20 | -9.10 | -8.37 | -6.34 | -17.00 | -16.10 | -15.09 | -13.19 | -124.61 | -1.53 | -1.00 | - | -111.42 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
17.42 | 17.10 | 15.86 | 11.16 | 7.90 | 4.57 | 14.79 | 7.17 | -3.05 | -3.16 | -8.33 | -23.23 | -26.47 | -17.95 | -21.41 | -19.92 | -18.81 | -10.71 | -13.81 | -12.55 | -10.58 | -7.01 | -9.05 | -8.52 | -8.29 | -6.57 | -8.94 | -8.86 | -8.15 | -6.18 | -16.20 | -15.34 | -14.36 | -12.51 | -27.27 | -1.51 | -0.99 | - | -14.76 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
15.92 | 15.29 | 13.62 | 11.01 | 6.40 | 2.72 | -0.72 | -9.08 | -20.07 | -19.24 | -25.05 | -26.76 | -30.09 | -20.11 | -23.95 | -22.05 | -20.24 | -11.08 | -14.40 | -12.94 | -11.06 | -7.73 | -10.36 | -9.95 | -9.88 | -7.85 | -10.47 | -10.00 | -9.11 | -6.80 | -11.03 | -9.85 | -8.63 | -6.62 | -118.03 | -1.45 | -0.94 | - | -111.42 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
10.6 | 11.6 | 12.1 | 11.7 | 12.0 | 9.7 | 10.2 | 11.7 | 15.8 | 20.6 | 23.0 | 22.1 | 12.6 | 15.4 | 16.2 | 14.3 | 9.0 | 19.1 | 10.5 | 17.7 | 35.8 | 16.6 | 16.6 | 16.6 | 16.6 | 34.2 | 34.2 | 34.2 | 34.2 | 40.2 | 40.2 | 40.2 | 40.2 | 78.3 | 21.3 | 78.3 | 78.3 | 1.1 | 1.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
101.7 | 100.6 | 112.5 | 102.0 | 107.6 | - | 109.1 | 135.0 | 148.0 | - | 49.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 112.5 | 102.0 | 107.6 | - | 109.1 | 135.0 | 148.0 | - | 49.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 112.5 | 102.0 | 107.6 | - | 109.1 | 135.0 | 148.0 | - | 49.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Krystal Biotech, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
